NCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
23 trialsNCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT00405405 2025-05-06
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase 1 Completed
NCT04091217 2024-10-24
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT00790010 2023-05-11
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00591734 2021-11-24
RAD001 Plus Bevacizumab in Metastatic Melanoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT01069627 2018-12-06
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT00074308 2018-06-20
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00387751 2017-11-22
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00434252 2017-07-18
BEAM
Genentech, Inc.
Phase 2 Completed
NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed
NCT00976573 2017-04-04
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00026221 2016-03-17
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00139360 2015-08-27
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
Haukeland University Hospital
Phase 2 Completed
NCT00462423 2014-01-08
AbraxAvast
Northern California Melanoma Center
Phase 2 Completed
NCT00255762 2013-10-28
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01743157 2013-08-29
BBI
California Pacific Medical Center Research Institute
Phase 1/2 Completed
NCT00568048 2013-04-10
Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Swiss Cancer Institute
Phase 2 Completed
NCT01048554 2012-04-19
MEL0107
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed